Santarus — Investor Day (January 2011)
108 slides from Santarus's investor day presentation, Jan 20, 2011
Slide 1: Analyst Day and Investor Briefing
NasdaqGS: SNTS Analyst Day and Investor Briefing January 19, 2011
Slide 2: Safe Harbor
Safe Harbor This presentation may include forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Santarus that any of its
Slide 3: Agenda
Agenda Welcome Martha L. Hough, Vice President, Finance and Investor Relations, Santarus, Inc. Strategic Overview and 2011 Financial Outlook Gerald T. Proehl, President, Chief Executive Officer & Director, Santarus, Inc. Cycloset(r) - Clinical/Medical Background Dr. J. Michael Gaziano, Chief, Divisi
Slide 4: Agenda - Continued
Agenda - Continued Ulcerative Colitis - Treatment Perspective Dr. William J. Sandborn, Professor of Clinical Medicine and Chief of the Division of Gastroenterology, University of California, San Diego Rhucin(r) and Hereditary Angioedema (HAE) Dr. Bruce L. Zuraw, Professor of Medicine and Chief, Alle
Slide 5: Santarus Business Strategy
Santarus Business Strategy Develop and commercialize proprietary pharmaceutical products Address unmet medical needs of patients treated by physician specialists Balance product portfolio and investments in R&D and SG&A to achieve meaningful, sustainable growth in revenues and profits Business decis
Slide 6: Attractive Mix of Commercial & Development Opportunities
Santarus Offers Attractive Mix of Commercial & Development Opportunities Development Opportunities Development Opportunities *Zegerid(r) is a non-promoted prescription product that continues to generate revenue. In addition, Zegerid OTC(r) is promoted by Merck Consumer Care. GlaxoSmithKline and Norg
Slide 7: Product Focus - Create Competitive Advantage
Product Focus - Create Competitive Advantage Product Focus - Create Competitive Advantage Unmet Medical Needs Multiple Indications Multiple Formulations Patents and/or Technology Product Differentiation Balanced Portfolio Pricing Flexibility January 19, 2011 7
Slide 8: Specialty Focus - Leverage Commercial Investment
Specialty Focus - Leverage Commercial Investment Sales Reps Physician Specialist Today Near Term Long Term Products & Product Candidates 110 Endocrinologists X Glumetza(r)Cycloset(r) +80 Gastroenterologists X Ultesa(tm)Rifamycin SV MMX(r)SAN-300 +25 Allergists/Immunologists X Rhucin(r)SAN-300 +30 Rh
Slide 9: Financial Focus - Increase Shareholder Value
Financial Focus - Increase Shareholder Value Sales per Rep Revenue SG&A as % Revenue R&D as % Revenue Profits & Cash Flow January 19, 2011 9
Slide 10: Historical Financial Performance 2005 - 2009
Historical Financial Performance 2005 - 2009 Total Revenue $27 $49 $94 $130 $172 Net Income (Loss) 2004 2005 2006 2007 2008 2009 Net Loss -83 -65 -56 -44 -18.5 32.1 2005 2006 2007 2009 2008 - -$65 - -$56 - -$44 - -$19 $32 ($ Millions) January 19, 2011 10
Slide 11: Financial Results through September 2010
Three Months Ended Sept 30, *First quarter of generic competition for Zegerid(r) **Includes $7.3 million in restructuring costs and $15 million upfront for Rhucin agreement Cash, cash equivalents & short-term investments: $65.1 million at September 30, 2010 Financial Results through September 2010 (
Slide 12: 2011 Financial Outlook
2011 Financial Outlook Expect top-line revenue growth to be positively impacted by resupply of Glumetza(r) 500 mg and launch of Cycloset(r) Realize benefit from full year impact of 3Q 2010 restructuring, which significantly reduced commercial infrastructure Estimate revenues of at least $110 million
Slide 13: Near Term Value Drivers for Santarus
Near Term Value Drivers for Santarus Glumetza(r) return to revenue growth Cycloset(r) educate endocrinologists and establish sales momentum Rhucin(r) BLA acceptance for FDA review expected in February 2011 Initiation of Rhucin Phase III study sites in HAE in January 2011 Estimate 12 to 18 months to
Slide 14: J. Michael Gaziano, MD, MPH
J. Michael Gaziano, MD, MPH Professor of Medicine, Harvard Medical School Chief, Division of Aging, Brigham and Women's Hospital
Slide 15: Accountant with Early Diabetes
Accountant with Early Diabetes 59-year-old man No history of CVD Father died at age 45 of MI Nonsmoker BP: 144/89 mm Hg (treated) BMI 29 Lipid parameters Total cholesterol: 243 mg/dL LDL-C: 172 mg/dL HDL-C: 36 mg/dL Triglycerides: 168 mg/dL Fasting Blood Sugar 138 January 19, 2011 15
Slide 16: Classification of Interventions
Classification of Interventions Class I Basic and observational research support causal association Intervention studies document benefit of modification Cost- and risk-benefit data available Class II Basic and observational research support causal association Intervention data are limited No cost ^
Slide 17: Class I and II Risk Factors/Interventions
Class I Class II Smoking Dyslipidemia Hypertension Prophylactic Meds: Aspirin Diabetes / Pre-Diabetes Physical inactivity Obesity Diet / Alcohol intake Gaziano, Ridker, Libby; in Heart Disease, Braunwald. Class I and II Risk Factors/Interventions January 19, 2011 17
Slide 18: Antidiabetic Therapies Lack Evidence of Efficacy in Reducing CVD Events
Antidiabetic Therapies Lack Evidence of Efficacy in Reducing CVD Events Current therapies were initially approved on the basis of glucose and HbA1C endpoints. Tight glucose control may delay progression of retinopathy, renal disease, and neuropathy, but there are limited data in the prevention of ma
Slide 19: Previous Trials of Tight vs. Conventional Glycemic Control
Study CVD MortalityRR (95% CI) Nonfatal MIRR (95% CI) Fatal and Nonfatal StrokeRR (95% CI) UKPDS, 1998 0.81 (0.65 - 1.02) 1.12 (0.83 - 1.52) 1.12 (0.83 - 1.52) VADT, 2009 1.32 (0.83 - 2.11) 0.78 (0.55 - 1.11) 0.78 (0.48 - 1.27) ADVANCE, 2008 0.88 (0.74 - 1.03) 0.98 (0.79 - 1.22) 0.97 (0.81 - 1.15) A
Slide 20: Insulin-resistance State
Highly conserved trait over 400 million years of vertebrate evolution. Confers a major survival advantage. Seasonally induced; centrally controlled through circadian neuroendocrine systems. Deleterious when it becomes over-expressed and permanent. Inherent plasticity in these central systems permits
Slide 21: Annual Cycle of Body Fat Levels in White-throated Sparrows
Body fat (%) dry weight May August Annual Cycle of Body Fat Levels in White-throated Sparrows January 19, 2011 21
Slide 22: Influences on Peripheral Metabolism
Daylight, diet, activity Influences on Peripheral Metabolism Circadian "Clock" Governs Other Hypothalamic Metabolic Control Centers January 19, 2011 22
Slide 23: Seasonal Variation Among Hunter-gatherers and Western Populations
Seasonal Variation Among Hunter-gatherers and Western Populations % body fat Years % body fat Years January 19, 2011 23 Hunter-gatherers Western Populations
Slide 24: Cycloset (bromocriptine mesylate)
Scraton R. BMC Endocrine Disorders 2007:7:1-3 Cycloset(r) (bromocriptine mesylate) Cycloset is the first and only centrally-acting dopamine agonist for the treatment of adults with type 2 diabetes that reduces insulin resistance resulting in a decrease in hepatic glucose output and an increase in ti
Slide 25: Cycloset: Proposed Mechanism of Action
Cycloset(r): Proposed Mechanism of Action Morning administration (within 2 hours of waking) of CYCLOSET Corrects Restoration of morning peak in dopaminergic activity (via D2 receptor-mediated activity) Decreased postprandial glucose levels Reduction in insulin resistance Day-long reduction in plasma
Slide 26: Cycloset Efficacy and Safety
Cycloset(r) Efficacy and Safety* *Please see www.Cycloset.com for full prescribing and safety information
Slide 27: Summary of Cycloset Phase III Efficacy Data
Summary of Cycloset(r) Phase III Efficacy Data Four phase III studies that evaluated safety and efficacy1,2 One 24-week monotherapy trial (n = 159) Cycloset plus diet and exercise compared to placebo Two 24-week add-on to sulfonylurea trials (n = 494) Cycloset plus SU compared to placebo plus SU One
Slide 28: Effect of Cycloset Monotherapy on Diurnal Plasma Glucose Levels
† ANOVA analysis of treatment and hour indicate a significant treatment effect over the entire diurnal (7 am to 7 pm) period (p<0.02) *Significantly different from control (p<0.05) Decrement in A1c (-0.6%, p=0.018) at 24 weeks - -40 0 40 - -31 - -35 - -39* - -31 - -49 - -47* - -16 - -23 - -32* Place
Slide 29: Effect of Cycloset on Plasma Triglyceride and FFA Levels
Scranton and Cincotta. Expert Opin Pharmacother 2010;11:269-7 29% P<0.01 19% P<0.02 - -200 - -100 0 100 200 Plasma FFA- Change From Baseline (meg/L) - -150 - -195 - -180 - -114 - -169 - -183 - -136 - -166 - -109 Placebo CYCLOSET Fasting FFA = 850 ?g/L ?TG vs Placebo - -80 - -40 0 40 80 - -91 - -111
Slide 30: Cycloset Safety Trial: 24 Week Evaluation of A1c Reduction
Data on file, Santarus, Inc Scranton et al, Diabetologia 2008; 51 (Suppl. 1): S372-373. Poster, EASD 2008. Rome, Italy Cincotta et al, Diabetologia 2008; 51 (Suppl. 1): S22. Poster, EASD 2008. Rome, Italy 0.6% to 0.9% HbA1c reductions vs. placebo when Cycloset added to other oral antidiabetics (OAD)
Slide 31: Cycloset: Summary of Efficacy
Cycloset (r): Summary of Efficacy Following once-daily, early morning administration of Cycloset: Cycloset controlled glucose throughout the day, reducing postprandial glucose without increasing insulin levels Cycloset reduced HbA1c by 0.6%-0.9% vs. placebo when added to other oral antidiabetics Cyc
Slide 32: Cycloset Safety Trial
Cycloset(r) Safety Trial Phase III Clinical Trial Where Overall Safety and CV Safety Were the Primary Objectives Diabetes Care July 2010 January 19, 2011 32
Slide 33: Cycloset Safety Trial Design
Cycloset(r) Safety Trial 52 Week, 74 Center RCT, Assessed the Safety (All Cause Serious Adverse Events and CVD Safety) and Efficacy of Cycloset in a Broad Patient Population of Adults with Type 2 Diabetes Mellitus (n = 3070) Real World Patient Population - Broad Inclusion Criteria Age 30 - 80 years
Slide 34: KM Curve - Composite CVD Endpoint
*MI, Stroke, hospitalization unstable angina, hospitalization CHF, or coronary revasc. KM Curve: the separation in favor of Cycloset begins 3 months and persists through the end of the study HR 0.58 (95% CI 0.35-0.96) RRR=42% KM Curve - Cycloset(r) Safety Trial Cumulative Percent Composite CVD Endpo
Slide 35: KM Curve - MACE Endpoint
ADA in abstract 2008 HR 0.45 (95% CI 0.2-0.99) KM Curve: the separation in favor of Cycloset begins 3 months and persists through the end of the study RRR= 55% KM Curve - Cycloset(r) Safety Trial Cumulative Percent MACE Endpoint January 19, 2011 35
Slide 36: Summary
Summary First centrally acting dopamine agonist for the treatment of type 2 diabetes in adults Unique formulation with no therapeutic equivalent Decreases post-meal hyperglycemia without increasing plasma insulin release Reduces HbA1c between 0.4 - 0.9% alone or in combination with anti-diabetes med
Slide 37: Accountant with Early Diabetes
Accountant with Early Diabetes January 19, 2011 37 59-year-old man No history of CVD Father died at age 45 of MI Nonsmoker BP: 144/89 mm Hg (treated) BMI 29 Lipid parameters Total cholesterol: 243 mg/dL LDL-C: 172 mg/dL HDL-C: 36 mg/dL Triglycerides: 168 mg/dL Fasting Blood Sugar 138
Slide 38: Overview of Budesonide MMX (Ultesa) Phase III Results
Overview of Budesonide MMX(r) (Ultesa(tm)) Phase III results: US and EU trials Simon Travis, DPhil FRCP Translational Gastroenterology Unit Oxford, UK
Slide 39: Ulcerative Colitis
Diffuse, mucosal inflammation Characterised by bloody diarrhoea (96%), Distribution: proctitis (40%), distal (40%), extensive (20%) Activity: Remission (50%), mild or moderate (45%/yr), severe (5%/year) EU: About 500,000 cases of UC (120 cases/100000 and 456m population in EU25) Costs €1800 per pati
Slide 40: Crohn's Disease
Crohn's Disease Patchy, transmural inflammation Characterized by pain, non-bloody diarrhoea and weight loss Distribution: terminal ileal (30%), colonic (30%), ileocolic (30%), other Variable pattern: inflammatory, fistulating, or stricturing Differs from UC Only 30% have isolated colonic disease Str
Slide 41: Management of Mild to Moderate UC
Oral 5-ASA Mesalazine 1.5-4.8 g/d Balsalazide 6.75 g/d Sulfasalazine 4-6 g/d Extensive (pancolitis) Rectal 5-ASA Induction 5-ASA, AZA/6-MP, infliximab Corticosteroids ECCO Consensus on UC: management J Crohn's & Colitis 2008;2:24-56. Infliximab Maint +- 1st-Line 2nd-Line 3rd-Line Management of Mild
Slide 42: Recognition of Need for Better Therapy
Recognition of Need for Better Therapy January 19, 2011 42
Slide 43: Budesonide and the Multi Matrix System (MMX)
Inert matrix Hydrophilic matrix Budesonide and the Multi Matrix System (MMX(r)) Gastroprotectant layer LV hydrophilic - amphipatic polymer matrix HV hydrophilic polym. matrix Inert matrix material Drug (+ excipient) January 19, 2011 43
Slide 44: Budesonide MMX 9mg
Budesonide MMX(r) 9mg Budesonide Highly potent corticosteroid Low systemic bioavailability Established value as topical therapy in UC and targeted delivery for CD Budesonide MMX (Ultesa(tm)) Gastro-resistant MMX delivery Two large phase III trials in UC NCT00679380 MMX 9mg vs 6mg vs Entocort (r) vs
Slide 45: Ultesa Phase III Study Design
Ultesa(tm) Phase 3 Study Design US & EU Studies US & EU Studies US & EU Studies January 19, 2011 45
Slide 46: Ultesa Phase III Headline Results
Ultesa(tm) Phase 3 Study Data Headline Results: US & EU Studies Ultesa 9 mg met statistical significance on the primary endpoint for both US & EU studies: p-value 0.0143 (US); 0.0047 (EU) The frequency of treatment-related adverse events and serious adverse events including potential glucocorticoid-
Slide 47: Primary Endpoint Efficacy Analysis (US & EU Studies)
(CHART) (CHART) U.S. Phase III Clinical Study (N= 489) E.U. Phase III Clinical Study (N= 410) 7.4% 13.2% 12.1% 4.5% 17.4%* 8.3% 12.6%** Placebo n=121 Placebo N=89 Ultesa 9mg n=123 Ultesa 9mg N=109 Ultesa 6mg n=121 Ultesa 6mg N=109 Asacol(r) n=124 Entocort(r) EC n=103 * Statistically significant vs.
Slide 48: Primary Endpoint Efficacy Analysis Tables
US Study CB-01-02/01 PlaceboN= 121n (%) MMX 9 mgN= 123n (%) MMX 6 mgN= 121n (%) AsacolN= 124n (%) Patients in Remission 9 (7.4) 22 (17.9) 16 (13.2) 15 (12.1) p-value 0.0143 0.1393 0.2200 EU Study CB-01-02/02 PlaceboN= 89n (%) MMX 9 mgN= 109n (%) MMX 6 mgN= 109n (%) EntocortN= 103n (%) Patients in Re
Slide 49: Impact of Different Definitions on Outcomes
Impact of Different Definitions on Outcomes Differences in defining remission 'within' a clinical trial ASCEND I and II studies: retrospective analysis1 EGF study: in-study analysis2 Katz et al. Gastroenterol 2006;130(Suppl 2):A-482. Abstract. T1136 Sinha et al. N Eng J Med 2003;349:350-357 Study AS
Slide 50: Contrasting Remission Rates Lialda and Ultesa
Contrasting Remission Rates Lialda(r) and Ultesa(tm) Protocol Design Differences Lialda(r) and Ultesa(tm) Protocol Design Differences Lialda(r) and Ultesa(tm) Protocol Design Differences January 19, 2011 50
Slide 51: Ultesa Phase III Safety Assessment
Treatment related AE data from U.S. and E.U. studies Ultesa(tm) Phase 3 Safety Assessment Adverse Event Profile January 19, 2011 51
Slide 52: Ultesa Phase III Safety Assessment: Plasma Cortisol
Ultesa(tm) Phase 3 Safety Assessment Plasma Cortisol (Pooled Data) Symbols indicate the mean plasma Cortisol level for each visit for each treatment. Error bars indicate the 25th and 75th percentiles. Treatments are offset for ease of readability. January 19, 2011 52
Slide 53: Conclusions
Conclusions Budesonide MMX(r) (Ultesa(tm)) was shown to induce remission in active ulcerative colitis in two Phase III clinical studies Two Phase III studies: US and EU, 1020 patients enrolled Robust selection: histological disease activity at baseline (quality control) Real remission: no bleeding,
Slide 54: January 19, 2011 54
January 19, 2011 54
Slide 55: Perspective on Treatment of Ulcerative Colitis in the U.S.
Perspective on Treatment of Ulcerative Colitis in the U.S. William J. Sandborn, M.D. University of California San Diego La Jolla, California
Slide 56: Estimates of IBD Prevalence - North America
Estimates of IBD Prevalence - North America Estimates of IBD Prevalence - North America Ingle SB, et al. Gastroenterology 2007;132(Suppl):A19. Bernstein CN, et al. Am J Gastroenterol 2006;101:1559. Herrinton LJ, et al. Inflamm Bowel Dis 2007;13:451. Kappelman MD, et al. Clin Gastroenterol Hepatol 20
Slide 57: Management of UC
Oral 5-ASAs Mesalamine 1.5-4.8 g/d Balsalazide 6.75 g/d Sulfasalazine 4-6 g/d Distal (left-sided, proctitis) Rectal 5-ASA or Rectal steroid Induction 5-ASA, AZA/6-MP, infliximab Oral steroid AZA/6-MP Kornbluth A, Sachar D. Am J Gastroenterol. 2004;99:1371. Baumgart DC, Sandborn WJ. Lancet. 2007;369:
Slide 58: 5-ASA Formulations
Delayed-Release: pH-dependent soluble polymer- coated tablets (release at pH ^7) Delayed Release: Gastro-resistant polymer film- coated tablets (release at pH ^7) Azo-Bonded Agents1 Controlled Release: Ethylcellulose-coated microgranules (time-dependent release) Lialda? Inert carrier Balsalazide Ols
Slide 59: 5-Aminosalicylate (5-ASA, Mesalamine) for UC
5-Aminosalicylate (5-ASA, Mesalamine) for UC Effective for induction and maintenance of response and remission in mild to moderate UC Advances More formulations No clear differences in efficacy Higher unit doses Some can be given once daily No clear dose response above 2.4 g/day January 19, 2011 59
Slide 60: Delayed Release Oral Mesalamine: Mild-to-Moderate Active UC
Significant Improvement Placebo 23 Mesalamine 1.6 g 43 Mesalamine 2.4 g 49 Remission Placebo 5 Mesalamine 1.6 g 14 Mesalamine 2.4 g 14 *Mucosal healing not assessed †Defined as "in remission" (complete resolution of all symptoms with all assessment scores = 0), OR "improved" (reduction in PGA score
Slide 61: Remission at Week 8 With Delayed-Release Mesalamine
Kamm1 -2.4 g/day in divided doses, 4.8 g/day as a single daily dose Lichtenstein2 -2.4 and 4.8 g/day as a single daily dose 1. Kamm MA. Gastroenterology. 2007;132:66. 2. Lichtenstein GR. Clin Gastroenterol Hepatol. 2007;5:95. Patients in Clinical and Endoscopic Remission at Week 8 (%) 0 10 20 30 40
Slide 62: Delayed Release Oral Mesalamine: Maintenance of Endoscopic Remission
Treatment Success Placebo 48 Mesalamine 0.8 g 63 Mesalamine 1.6 g 70 †Defined as "maintenance of endoscopic remission at 6 months" (score of 0 out of 3 on sigmoidoscopic scale) ‡P=.05 §P=.005 Hanauer SB et al. Ann Intern Med. 1996;124:204. ‡ § † Percent of patients Delayed Release Oral Mesalamine: U
Slide 63: Steroids for UC
Steroids for UC Effective for induction of response and remission in moderate to severe UC Advances No long term efficacy Increased risk of infection and mortality January 19, 2011 63
Slide 64: Oral Cortisone: Clinical Response and Remission at 6 Weeks
Clinical response Clinical remission Placebo (n=101) 41 16 Cortisone (n=109) 69 41 *Clinical remission defined as 1 or 2 stools/day without blood †Clinical response defined as improved or clinical remission Truelove SC. Br Med J. 1954;4884:375. P<0.001 P<0.001 * † Oral Cortisone: Mild-to-Severe Acti
Slide 65: Oral Cortisone: Mucosal Healing at 6 Weeks
Mucosal healing Placebo (n=57) 11 Cortisone 100 mg/d (n=63) 30 *Defined as normal or near normal (slight hyperemia or granularity) mucosa Truelove SC. Br Med J. 1954;4884:375. P=.02 * Oral Cortisone: Mild-to-Severe Active Ulcerative Colitis: Mucosal Healing at 6 Weeks January 19, 2011 65
Slide 66: Mortality Associated with Current and Recent Corticosteroid Use
Lewis JD, et al. Am J Gastroenterol. 2008;103:1428-1435. Hazard Ratio 95% CI: (2.26-3.5) 95% CI: (1.65-3.75) Recent Use of Corticosteroids Current Use of Corticosteroids Mortality Associated with Current and Recent Corticosteroid Use - Adjusted HR (95% CI) January 19, 2011 66
Slide 67: Azathioprine for UC
Azathioprine for UC Widely used for maintenance of remission and steroid sparing in moderate to severe UC Advances Meta-analysis showed equivocal/ modest efficacy 4-fold increase in risk of non-Hodgkins lymphoma (majority linked to EBV) January 19, 2011 67
Slide 68: Efficacy of AZA for Treatment Success in UC: Meta-Analysis
Estimate of Efficacy of AZA for Treatment Success in UC Patients: Meta-Analysis Leung Y, et al. Dig Dis Sci. 2008;53:1455-1461. Pooled RR Estimate Across Five Trials January 19, 2011 68
Slide 69: Toxicity of Azathioprine and 6-Mercaptopurine in IBD
Toxicity of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease Opportunistic Infections Lymphoma Meta-analysis of 6 studies showed that AZA/6MP treatment is associated with 4-fold increase (SIR = 4.2 [95% CI = 2.1 - 7.5]) in risk of EBV-positive lymphoma Bone marrow depression (leukopen
Slide 70: Anti-TNF Antibody (Infliximab) for UC
Anti-Tumor Necrosis Factor Antibody (Infliximab) for UC Induces and maintains clinical response and remission, mucosal healing, and steroid sparing January 19, 2011 70
Slide 71: Infliximab Induction and Maintenance Therapy: Clinical Remission
†P?.003 vs placebo ‡P<.001 vs placebo 8 Weeks 30 Weeks Placebo 6 11 IFX 5 mg/kg 34 26 IFX 10 mg/kg 28 36 8 Weeks 30 Weeks 54 Weeks Placebo 15 16 17 IFX 5 mg/kg 39 34 35 IFX 10 mg/kg 32 37 34 ‡ ‡ ‡ † † ‡ ‡ ‡ ACT 1 ACT 2 ‡ ‡ Rutgeerts P. N Engl J Med. 2005;353:2462. Infliximab Induction and Maintenanc
Slide 72: Anti-TNF Antibody Toxicity
Anti-TNF Antibody Toxicity Non-Hodgkin's lymphoma Hepatosplenic T cell lymphoma in children on infliximab or adalimumab + azathioprine ? Skin cancer ? Solid tumors Serious infections Opportunistic Infections (including granulomatous infections such as tuberculosis and histoplasmosis) January 19, 201
Slide 73: Surgical Options in Ulcerative Colitis
Conventional ileostomy (Brooke) Continent ileostomy (Kock pouch) Ileal pouch-anal anastomosis Ileorectal anastomosis CP1288478-73 Surgical Options in Ulcerative Colitis January 19, 2011 73
Slide 74: Risks Of Surgical Therapy For Ulcerative Colitis
Risks Of Surgical Therapy For Ulcerative Colitis Increased stool frequency (median 6/day, 1/night) Fecal incontinence Pouchitis (50%) Cuffitis (? 20%) Reoperation for SBO due to adhesions Reoperation for ventral hernia Female infertility (50%) Permanent stoma (30-40%) Pouch excision (10%) Mortality
Slide 75: Potential Role of Budesonide MMX (Ultesa) in the Therapy of UC
Potential Role of Budesonide MMX(r) (Ultesa(tm)) in the Therapy of UC Primary induction therapy Induction therapy in patients failing mesalamine Adjunctive therapy in patients receiving azathioprine, 6- mercaptopurine or infliximab Maintenance therapy in patients who received induction therapy with
Slide 76: Conclusions
Conclusions Ulcerative colitis is a chronic condition with high morbidity Many patients treated with mesalamine do not achieve remission Treatment with conventional steroids, azathioprine and 6-mercaptopurine, and infliximab has important limitations Surgery is not an optimal solution, it leads to i
Slide 77: Overview of HAE Treatment Options in the U.S.
Overview of HAE Treatment Options in the U.S. Bruce L. Zuraw, M.D. Chief, Allergy & Immunology, UCSD
Slide 78: Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE) January 19, 2011 78
Slide 79: Epidemiology of HAE
Epidemiology of HAE Estimated prevalence is difficult to ascertain Autosomal dominant inheritance Varying estimates of as high as 1 in 30,000 to as low as 1 in 80,000 Probably to 4000-10,000 affected individuals in United States No known ethnic or gender differences Average attack frequency in untre
Slide 80: HAE Attack Characteristics
HAE Attack Characteristics Angioedema, often quite severe Attacks prolonged Increasing intensity over first 24 hrs Resolving over next 2-4 days Pts may be ill 3-8 days or more per 2 weeks Extremity attacks Inability to go to work/school; Compartment syndromes Abdominal attacks Freq. need hospitaliza
Slide 81: Location and Onset of HAE Symptoms
Bork K, et al. Am J Med. 2006;119:267-274 Location and Onset of HAE Symptoms Retrospective study 221 HAE patients 5736 patient-years of observation 131,110 angioedema attacks January 19, 2011 81
Slide 82: Treatment of Acute HAE Attacks Pre-2008
Zuraw BL. N Engl J Med. 2008;359:1027-1036 Corticosteroids Antihistamines Epinephrine Treatment of Acute HAE Attacks Pre-2008 No reliable US FDA-approved therapy for acute attacks Extremity attacks No treatment given Often disabling Gastrointestinal attacks Often required hospitalization Risk of nar
Slide 83: Bradykinin is the Mediator of AE in HAE
Bradykinin is the Mediator of AE in HAE January 19, 2011 83
Slide 84: Bradykinin Theory: Therapeutic Implications
Zuraw BL. Immunol Allergy Clin North Am. 2006;26:691-708. Bradykinin Theory: Therapeutic Implications January 19, 2011 84
Slide 85: pdC1INH (Berinert) for Acute HAE Attacks
pdC1INH (Berinert(r)) for Acute HAE Attacks Craig, JACI 2009 p801 pdC1INH-p 20 U/kg bw (N=43) pdC1INH-p 10 U/kg bw (N=39) Placebo (N=42) P = 0.0025 vs placebo P = 0.2731 vs placebo January 19, 2011 85
Slide 86: pdC1INH-nf (Cinryze) for Acute HAE Attacks
Zuraw, NEJM 2010 p513 pdC1INH-nf (Cinryze(r)) for Acute HAE Attacks p = 0.019 vs placebo January 19, 2011 86
Slide 87: Ecallantide (Kalbitor) for Acute HAE Attacks
Riedl, Ann Allergy Asthma Immunol. 2010;105:430 Beginning of improvement Sustained improvement Plog rank = 0.09 Plog rank = 0.005 Plog rank = 0.04 Ecallantide (Kalbitor(r)) for Acute HAE Attacks Ecallantide Placebo January 19, 2011 87
Slide 88: Icatibant (Firazyr) for Acute HAE Attacks
Cicardi, NEJM 2010 p532 and Shire Press Release 12/1/10 FAST-1 (USA) FAST-2 (Europe) FAST-3 (World) p = 0.14 p < 0.001 p < 0.001 (N=44) (N=44) Icatibant (Firazyr(r)) for Acute HAE attacks January 19, 2011 88
Slide 89: Recombinant Human C1INH
Recombinant Human C1INH Recombinant human C1INH Rhucin(r) (Pharming/Santarus) hC1INH cDNA driven by mammary promoter rhC1INH from breast milk of transgenic rabbits Identical to plasma C1INH at protein level Post-translational (glycosylation) changes Inhibits proteases same as plasma C1INH January 19
Slide 90: rhC1INH (Rhucin) Pharmacokinetics
van Doorn, JACI, 116:876, 2005. rhC1INH (Rhucin(r)) Pharmacokinetics January 19, 2011 90
Slide 91: rhC1INH (Rhucin) for Acute HAE Attacks
d rhC1INH (Rhucin(r)) for Acute HAE Attacks Zuraw, JACI 126:821 2010 Time (hours) P = 0.013 P < 0.001 January 19, 2011 91
Slide 92: Emerging Guidelines for HAE Treatment
Emerging Guidelines for HAE Treatment Treatment should maximize patient health Abort attacks with early & effective treatment Minimize disruption of school, job, & sleep Avoid significant side effects Treatment should be individualized All patients should have effective therapy available to treat al
Slide 93: Rhucin Versus Other HAE Treatments
Rhucin(r) Versus Other HAE Treatments Rhucin advantages Drug supply is elastic and virtually inexhaustible Higher dosage normalizes C1-INH level and may be more effective in stopping attacks Lack of risk of infectious agents from human plasma Rhucin disadvantages Potential allergic reactions to rabb
Slide 94: Summary
Summary HAE is an uncommon but serious disease Key to minimizing morbidity and mortality is early recognition HAE results from C1INH mutations Bradykinin is the mediator of swelling Historical treatments variably effective but suboptimal New consensus emerging for improved treatment outcomes Emergin
Slide 95: SAN-300 (Anti-VLA-1 Antibody)
SAN-300 (Anti-VLA-1 Antibody) Mark C. Totoritis, M.D. Senior Vice President, Biologics Santarus, Inc. SAN-300 (Anti-VLA-1)
Slide 96: SAN-300 (Anti-VLA-1) Overview
SAN-300 (Anti-VLA-1) Overview Novel approach to autoimmune/inflammatory disease therapy The Target Integrin VLA-1 (?1?1 integrin) Major collagen receptor Expressed on activated T cells and monocytes VLA-1 mediates migration, retention and proliferation of these cells at sites of inflammation January
Slide 97: VLA-1 Mediates Cell-Matrix Interactions
VLA-1 Mediates Cell-Matrix Interactions January 19, 2011 97
Slide 98: SAN-300 (Anti-VLA-1) Overview
SAN-300 (Anti-VLA-1) Overview SAN-300 Humanized IgG1? antibody manufactured by recombinant expression in mammalian cells Binds ?1 subunit of VLA-1 with high affinity and inhibits adhesion to matrix molecules at low antibody concentration Non-depleting Existing drug supply adequate for early phase cl
Slide 99: Anti-VLA-1 Preclinical Efficacy
Anti-VLA-1 Preclinical Efficacy Strong efficacy in multiple preclinical models Rheumatoid arthritis Inflammatory bowel disease Psoriasis Corneal transplant Kidney disease (nephritis) Asthma Others January 19, 2011 99
Slide 100: Anti-VLA-1 Reduces Cellular Infiltrate And Joint Erosion
Normal Arthritic - IgG Control Arthritic - a1 Treated H&E Toluidine blue Anti-VLA-1 Reduces Cellular Infiltrate And Joint Erosion de Fougerolles et al. J Clin Invest 2000;105:721-29 January 19, 2011 100
Slide 101: Anti-VLA-1 Inhibits Inflammation In DSS Colitis Model
Krieglstein et al. J.Clin Invest 2002;110:1773-82 Anti-VLA-1 Inhibits Inflammation In DSS Colitis Model January 19, 2011 101
Slide 102: Anti-VLA-1 Inhibits Inflammation In Psoriasis Model
Anti-VLA-1 Inhibits Inflammation In Psoriasis Model In Psoriasis Model In Psoriasis Model Conrad et al. Nat Med 2007;13:836-42 January 19, 2011 102
Slide 103: VLA-1+ T cells Correlate With Disease State in Human RA
Ben-Horin et al. J Clin Immunol 2007;27:580-88 VLA-1+ T cells Correlate With Disease State in Human RA January 19, 2011 103
Slide 104: Rheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid Arthritis January 19, 2011 104
Slide 105: SAN-300 Initial Indication
SAN-300 Initial Indication Initial indication: Rheumatoid arthritis Strong technical rationale Efficacy in multiple arthritis models - both prophylactic and therapeutic protocols High unmet medical need ?50% inadequate response to TNF inhibitors Clear development and regulatory path FDA guidance and
Slide 106: SAN-300 Proposed Phase I Study Design
SAN-300 Proposed Phase I Study Design Randomized, placebo-controlled, blinded, single-center, single-dose, dose-escalation study Objectives Primary: to evaluate safety and tolerability of single doses of anti-VLA-1Secondary: to characterize the PK and PD of single doses of anti-VLA-1 Sample Size &Tr
Slide 107: Attractive Mix of Commercial & Development Opportunities
Santarus Offers Attractive Mix of Commercial & Development Opportunities Development Opportunities Development Opportunities *Zegerid(r) is a non-promoted prescription product that continues to generate revenue. In addition, Zegerid OTC(r) is promoted by Merck Consumer Care. GlaxoSmithKline and Norg
Slide 108: Question & Answer Session
Question & Answer Session